Literature DB >> 3118825

Pregnancy following induction of ovulation with pure FSH after suppression of endogenous gonadotropins with subcutaneous buserelin.

P J Albert1, J Schläfke, H Kaesemann, J Gille.   

Abstract

Ovarian stimulation in patients with disorders of ovulation or an inadequate luteal phase using human menopausal gonadotropins (hMG) gives a low pregnancy rate with a high incidence of overstimulation and a premature LH surge. In order to overcome these problems, a new approach has been used, namely prior suppression of endogenous gonadotropins with a gonadotropin-releasing-hormone analog (LHRH) and subsequent ovarian stimulation with hMG. We present a case of ovarian stimulation with pure FSH during suppression of endogenous gonadotropins with the LHRH analog Buserelin. A clinical pregnancy was achieved in the first treatment cycle and led us to conclude that follicular development does not depend on LH stimulation. This could be of substantial interest in IVF programs.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3118825     DOI: 10.1007/bf00931442

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  8 in total

1.  Induction of multiple follicular growth in normally menstruating women with endogenous gonadotropin suppression.

Authors:  R Fleming; J R Coutts
Journal:  Fertil Steril       Date:  1986-02       Impact factor: 7.329

2.  The microenvironment of the human antral follicle: interrelationships among the steroid levels in antral fluid, the population of granulosa cells, and the status of the oocyte in vivo and in vitro.

Authors:  K P McNatty; D M Smith; A Makris; R Osathanondh; K J Ryan
Journal:  J Clin Endocrinol Metab       Date:  1979-12       Impact factor: 5.958

3.  Control of preovulatory follicular estrogen biosynthesis in the human ovary.

Authors:  S G Hillier; L E Reichert; E V Van Hall
Journal:  J Clin Endocrinol Metab       Date:  1981-05       Impact factor: 5.958

4.  Update on in vitro fertilization.

Authors:  G S Jones
Journal:  Endocr Rev       Date:  1984       Impact factor: 19.871

5.  Cumulative conception rates following gonadotropin therapy.

Authors:  J Dor; D J Itzkowic; S Mashiach; B Lunenfeld; D M Serr
Journal:  Am J Obstet Gynecol       Date:  1980-01-01       Impact factor: 8.661

6.  Gonadotropin therapy of female infertility. Analysis of results in 416 cases.

Authors:  R Zimmermann; B Soor; W Braendle; F Lehmann; H C Weise; G Bettendorf
Journal:  Gynecol Obstet Invest       Date:  1982       Impact factor: 2.031

7.  Ovulation induction in polycystic ovary syndrome with urinary follicle-stimulating hormone or human menopausal gonadotropin.

Authors:  M M Seibel; C McArdle; D Smith; M L Taymor
Journal:  Fertil Steril       Date:  1985-05       Impact factor: 7.329

8.  Successful treatment of infertile women with oligomenorrhoea using a combination of an LHRH agonist and exogenous gonadotrophins.

Authors:  R Fleming; M J Haxton; M P Hamilton; G S McCune; W P Black; M C MacNaughton; J R Coutts
Journal:  Br J Obstet Gynaecol       Date:  1985-04
  8 in total
  2 in total

Review 1.  Buserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical profile.

Authors:  R N Brogden; M M Buckley; A Ward
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

2.  Design of a long-acting follitropin agonist by fusing the C-terminal sequence of the chorionic gonadotropin beta subunit to the follitropin beta subunit.

Authors:  F A Fares; N Suganuma; K Nishimori; P S LaPolt; A J Hsueh; I Boime
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-15       Impact factor: 11.205

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.